The use of anti-Bcl-2 mRNA agent (Oblimersen sodium, an 18-base antisense phosphorothioate oligonucleotide) has been studied for the treatment of lymphoma and it has also been tested in combination with other anticancer agents in various cancer types, such as multiple myeloma, small-cell lung cancer, melanoma and non-Hodgkin’s lymphoma24. This evidence concerns the gene BCL2 and AL amyloidosis.